OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacology & Therapeutics is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts. The publications cover those that have been published in the past four years, i.e., from 2019-03-01 to 2023-03-01.)

Article	Citations
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation	2406
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function	201
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy	187
Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas	182
Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases	165
An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients	152
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges	150
The role of DNA methylation in epigenetics of aging	144
The neuropsychopharmacology of cannabis: A review of human imaging studies	144
Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders	132
Recent therapeutic trends and promising targets in triple negative breast cancer	124
Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies	103
Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities	99
ATM in DNA repair in cancer	98
Senescence and senotherapeutics: a new field in cancer therapy	97
TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward	96
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer	96
The role of flavonoids in autoimmune diseases: Therapeutic updates	93
RNA therapy: Are we using the right molecules?	88
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders	87
Recent advances in the development of Mcl-1 inhibitors for cancer therapy	85
Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer	83
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies	83
Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics	83
Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease	81
Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases	81
Nanotechnology in the diagnosis and treatment of lung cancer	80
PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression	79
Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies	77
CD26/DPP4 - a potential biomarker and target for cancer therapy	75
DYRK1A and cognition: A lifelong relationship	73
Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR/transducer selectivity and therapeutic potential	73
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?	71
Antifungal drugs: New insights in research & development	71
Altered cancer metabolism in mechanisms of immunotherapy resistance	70
An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy	67
Heat shock proteins in fibrosis and wound healing: Good or evil?	67
Acute kidney injury overview: From basic findings to new prevention and therapy strategies	67
The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease	66
Super-enhancers in cancer	62
Statins: Adverse reactions, oxidative stress and metabolic interactions	61
Mesenchymal stem cells: From regeneration to cancer	60
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine	59
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence	59
Phosphodiesterases as therapeutic targets for respiratory diseases	59
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity	59
The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy	57